Two truncating variants in FANCC and breast cancer risk. by Dörk, Thilo et al.
UC Irvine
UC Irvine Previously Published Works
Title
Two truncating variants in FANCC and breast cancer risk.
Permalink
https://escholarship.org/uc/item/3qv7j31z
Journal
Scientific reports, 9(1)
ISSN
2045-2322
Authors
Dörk, Thilo
Peterlongo, Paolo
Mannermaa, Arto
et al.
Publication Date
2019-08-29
DOI
10.1038/s41598-019-48804-y
License
CC BY 4.0
 
Peer reviewed
eScholarship.org Powered by the California Digital Library
University of California
1Scientific RepoRtS |         (2019) 9:12524  | https://doi.org/10.1038/s41598-019-48804-y
www.nature.com/scientificreports
two truncating variants in FANCC 
and breast cancer risk
thilo Dörk1, paolo peterlongo2, Arto Mannermaa3,4,5, Manjeet K. Bolla6, Qin Wang6, 
Joe Dennis6, thomas Ahearn7, irene L. Andrulis  8,9, Hoda Anton-culver10, Volker Arndt  11,  
Kristan J. Aronson12, Annelie Augustinsson13, Laura e. Beane freeman7, 
Matthias W. Beckmann14, Alicia Beeghly-fadiel15, Sabine Behrens16, Marina Bermisheva17, 
carl Blomqvist18,19, natalia V. Bogdanova1,20,21, Stig e. Bojesen22,23,24, Hiltrud Brauch  25,27,156, 
Hermann Brenner11,27,28, Barbara Burwinkel29,30, federico canzian31, tsun L. chan32,33, 
Jenny chang-claude16,34, Stephen J. chanock7, Ji-Yeob choi35,36, Hans christiansen20, 
christine L. clarke37, fergus J. couch38, Kamila czene39, Mary B. Daly40, isabel dos-Santos-Silva41, 
Miriam Dwek  42, Diana M. eccles43, Arif B. ekici  44, Mikael eriksson39, D. Gareth evans45,46, 
peter A. fasching  14,47, Jonine figueroa  7,48,49, Henrik flyger50, Lin fritschi51, 
Marike Gabrielson39, Manuela Gago-Dominguez52,53, chi Gao54,55, Susan M. Gapstur56, 
Montserrat García-closas7,57, José A. García-Sáenz58, Mia M. Gaudet56, Graham G. Giles59,60,61,  
Mark S. Goldberg62,63, David e. Goldgar64, pascal Guénel65, Lothar Haeberle66, 
christopher A. Haiman67, niclas Håkansson68, per Hall39,69, Ute Hamann70, Mikael Hartman71,72, 
Jan Hauke73,74,75, Alexander Hein  14, peter Hillemanns1, frans B. L. Hogervorst76, 
Maartje J. Hooning77, John L. Hopper60, tony Howell78, Dezheng Huo79, Hidemi ito  80,81,  
Motoki iwasaki82, Anna Jakubowska83,84, Wolfgang Janni85, esther M. John86, Audrey Jung16,  
Rudolf Kaaks16, Daehee Kang35,36,87, pooja Middha Kapoor16,88, elza Khusnutdinova17,89, 
Sung-Won Kim90, cari M. Kitahara91, Stella Koutros7, peter Kraft54,55, 
Vessela n. Kristensen92,93, Ava Kwong32,94,95, Diether Lambrechts96,97, Loic Le Marchand98, 
Jingmei Li99, Sara Lindström100,101, Martha Linet91, Wing-Yee Lo25,26, Jirong Long15, 
Artitaya Lophatananon103, Jan Lubiński83, Mehdi Manoochehri70, Siranoush Manoukian104, 
Sara Margolin69,105, elena Martinez53,106, Keitaro Matsuo  80,81, Dimitris Mavroudis107, 
Alfons Meindl108, Usha Menon  109, Roger L. Milne  59,60,110, nur Aishah Mohd taib111,  
Kenneth Muir  102,103, Anna Marie Mulligan112,113, Susan L. neuhausen114, Heli nevanlinna  115, 
patrick neven116, William G. newman  45,46, Kenneth Offit117,118, olufunmilayo i. olopade79, 
Andrew f. olshan119, Janet e. olson120, Håkan olsson13, Sue K. park35,36,87,  
tjoung-Won park-Simon1, Julian peto  41, Dijana Plaseska-Karanfilska121, 
esther pohl-Rescigno73,74,75, nadege presneau42, Brigitte Rack85, paolo Radice122, 
Muhammad U. Rashid70,123, Gad Rennert  124, Hedy S. Rennert124, Atocha Romero  125,  
Matthias Ruebner66, emmanouil Saloustros126, Marjanka K. Schmidt  127,128, 
Rita K. Schmutzler73,74,75, Michael o. Schneider66, Minouk J. Schoemaker129,  
christopher Scott  120, chen-Yang Shen130,131, Xiao-ou Shu15, Jacques Simard132, 
Susan Slager120, Snezhana Smichkoska133, Melissa c. Southey110,134, John J. Spinelli135,136, 
Jennifer Stone  60,137, Harald Surowy29,30, Anthony J. Swerdlow129,138, Rulla M. tamimi54,55,139, 
William J. tapper140, Soo H. teo111,141, Mary Beth terry142, Amanda e. toland143, 
Rob A. e. M. tollenaar144, Diana torres70,145, Gabriela torres-Mejía146, Melissa A. troester119, 
thérèse truong  65, Shoichiro tsugane  147, Michael Untch148, celine M. Vachon149, 
Ans M. W. van den ouweland150, elke M. van Veen45,46, Joseph Vijai117,118, camilla Wendt105, 
Alicja Wolk68,151, Jyh-cherng Yu152, Wei Zheng15, Argyrios Ziogas  10, elad Ziv153, ABctB 
investigators*, nBcS collaborators*, Alison M. Dunning  165, paul D. p. pharoah  6,165, 
Detlev Schindler166, peter Devilee  167,168 & Douglas f. easton  6,165
Received: 13 March 2019
Accepted: 9 August 2019
Published: xx xx xxxx
open
2Scientific RepoRtS |         (2019) 9:12524  | https://doi.org/10.1038/s41598-019-48804-y
www.nature.com/scientificreportswww.nature.com/scientificreports/
1Gynaecology Research Unit, Hannover Medical School, Hannover, Germany. 2Genome Diagnostics Program, IFOM 
- the FIRC Institute of Molecular Oncology, Milan, Italy. 3Translational Cancer Research Area, University of Eastern 
Finland, Kuopio, Finland. 4Institute of Clinical Medicine, Pathology and Forensic Medicine, University of Eastern 
Finland, Kuopio, Finland. 5Imaging Center, Department of Clinical Pathology, Kuopio University Hospital, Kuopio, 
Finland. 6Centre for Cancer Genetic Epidemiology, Department of Public Health and Primary Care, University of 
Cambridge, Cambridge, UK. 7Division of Cancer Epidemiology and Genetics, National Cancer Institute, National 
Institutes of Health, Department of Health and Human Services, Bethesda, MD, USA. 8Fred A. Litwin Center for 
Cancer Genetics, Lunenfeld-Tanenbaum Research Institute of Mount Sinai Hospital, Toronto, ON, Canada. 
9Department of Molecular Genetics, University of Toronto, Toronto, ON, Canada. 10Department of Epidemiology, 
Genetic Epidemiology Research Institute, University of California Irvine, Irvine, CA, USA. 11Division of Clinical 
Epidemiology and Aging Research, C070, German Cancer Research Center (DKFZ), Heidelberg, Germany. 
12Department of Public Health Sciences, and Cancer Research Institute, Queen’s University, Kingston, ON, Canada. 
13Department of Cancer Epidemiology, Clinical Sciences, Lund University, Lund, Sweden. 14Department of 
Gynecology and Obstetrics, Comprehensive Cancer Center ER-EMN, University Hospital Erlangen, Friedrich-
Alexander-University Erlangen-Nuremberg, Erlangen, Germany. 15Division of Epidemiology, Department of 
Medicine, Vanderbilt Epidemiology Center, Vanderbilt-Ingram Cancer Center, Vanderbilt University School of 
Medicine, Nashville, TN, USA. 16Division of Cancer Epidemiology, German Cancer Research Center (DKFZ), 
Heidelberg, Germany. 17Institute of Biochemistry and Genetics of the Ufa Federal Research Centre of the Russian 
Academy of Sciences, Ufa, Russia. 18Department of Oncology, Helsinki University Hospital, University of Helsinki, 
Helsinki, Finland. 19Department of Oncology, Örebro University Hospital, Örebro, Sweden. 20Department of 
Radiation Oncology, Hannover Medical School, Hannover, Germany. 21N.N. Alexandrov Research Institute of 
Oncology and Medical Radiology, Minsk, Belarus. 22Copenhagen General Population Study, Herlev and Gentofte 
Hospital, Copenhagen University Hospital, Herlev, Denmark. 23Department of Clinical Biochemistry, Herlev and 
Gentofte Hospital, Copenhagen University Hospital, Herlev, Denmark. 24Faculty of Health and Medical Sciences, 
University of Copenhagen, Copenhagen, Denmark. 25Dr. Margarete Fischer-Bosch-Institute of Clinical Pharmacology, 
Stuttgart, Germany. 26University of Tübingen, Tübingen, Germany. 27German Cancer Consortium (DKTK), German 
Cancer Research Center (DKFZ), Heidelberg, Germany. 28Division of Preventive Oncology, German Cancer Research 
Center (DKFZ) and National Center for Tumor Diseases (NCT), Heidelberg, Germany. 29Molecular Epidemiology 
Group, C080, German Cancer Research Center (DKFZ), Heidelberg, Germany. 30Molecular Biology of Breast Cancer, 
University Womens Clinic Heidelberg, University of Heidelberg, Heidelberg, Germany. 31Genomic Epidemiology 
Group, German Cancer Research Center (DKFZ), Heidelberg, Germany. 32Hong Kong Hereditary Breast Cancer 
Family Registry, Cancer Genetics Centre, Happy Valley, Hong Kong. 33Department of Pathology, Hong Kong 
Sanatorium and Hospital, Happy Valley, Hong Kong. 34Cancer Epidemiology Group, University Cancer Center 
Hamburg (UCCH), University Medical Center Hamburg-Eppendorf, Hamburg, Germany. 35Department of Biomedical 
Sciences, Seoul National University Graduate School, Seoul, Korea. 36Cancer Research Institute, Seoul National 
University, Seoul, Korea. 37Westmead Institute for Medical Research, University of Sydney, Sydney, New South 
Wales, Australia. 38Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, MN, USA. 
39Department of Medical Epidemiology and Biostatistics, Karolinska Institutet, Stockholm, Sweden. 40Department 
of Clinical Genetics, Fox Chase Cancer Center, Philadelphia, PA, USA. 41Department of Non-Communicable Disease 
Epidemiology, London School of Hygiene and Tropical Medicine, London, UK. 42Department of Biomedical Sciences, 
Faculty of Science and Technology, University of Westminster, London, UK. 43Cancer Sciences Academic Unit, Faculty 
of Medicine, University of Southampton, Southampton, UK. 44Institute of Human Genetics, University Hospital 
Erlangen, Friedrich-Alexander University Erlangen-Nuremberg, Comprehensive Cancer Center Erlangen-EMN, 
Erlangen, Germany. 45Division of Evolution and Genomic Sciences, School of Biological Sciences, Faculty of Biology, 
Medicine and Health, University of Manchester, Manchester Academic Health Science Centre, Manchester, UK. 
46Manchester Centre for Genomic Medicine, St Mary’s Hospital, Manchester University Hospitals NHS Foundation 
Trust, Manchester Academic Health Science Centre, Manchester, UK. 47David Geffen School of Medicine, 
Department of Medicine Division of Hematology and Oncology, University of California at Los Angeles, Los Angeles, 
CA, USA. 48Usher Institute of Population Health Sciences and Informatics, The University of Edinburgh Medical 
School, Edinburgh, UK. 49Cancer Research UK Edinburgh Centre, Edinburgh, UK. 50Department of Breast Surgery, 
Herlev and Gentofte Hospital, Copenhagen University Hospital, Herlev, Denmark. 51School of Public Health, Curtin 
University, Perth, Western Australia, Australia. 52Genomic Medicine Group, Galician Foundation of Genomic 
Medicine, Instituto de Investigación Sanitaria de Santiago de Compostela (IDIS), Complejo Hospitalario Universitario 
de Santiago, SERGAS, Santiago de Compostela, Spain. 53Moores Cancer Center, University of California San Diego, 
La Jolla, CA, USA. 54Program in Genetic Epidemiology and Statistical Genetics, Harvard T.H. Chan School of Public 
Health, Boston, MA, USA. 55Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA, 
USA. 56Behavioral and Epidemiology Research Group, American Cancer Society, Atlanta, GA, USA. 57Division of 
Genetics and Epidemiology, Institute of Cancer Research, London, UK. 58Medical Oncology Department, Hospital 
Clínico San Carlos, Instituto de Investigación Sanitaria San Carlos (IdISSC), Centro Investigación Biomédica en Red de 
Cáncer (CIBERONC), Madrid, Spain. 59Cancer Epidemiology Division, Cancer Council Victoria, Melbourne, Victoria, 
Australia. 60Centre for Epidemiology and Biostatistics, Melbourne School of Population and Global Health, The 
University of Melbourne, Melbourne, Victoria, Australia. 61Department of Epidemiology and Preventive Medicine, 
Monash University, Melbourne, Victoria, Australia. 62Department of Medicine, McGill University, Montréal, QC, 
Canada. 63Division of Clinical Epidemiology, Royal Victoria Hospital, McGill University, Montréal, QC, Canada. 
64Department of Dermatology, Huntsman Cancer Institute, University of Utah School of Medicine, Salt Lake City, UT, 
USA. 65Cancer & Environment Group, Center for Research in Epidemiology and Population Health (CESP), INSERM, 
University Paris-Sud, University Paris-Saclay, Villejuif, France. 66Department of Gynaecology and Obstetrics, 
University Hospital Erlangen, Friedrich-Alexander University Erlangen-Nuremberg, Comprehensive Cancer Center 
Erlangen-EMN, Erlangen, Germany. 67Department of Preventive Medicine, Keck School of Medicine, University of 
3Scientific RepoRtS |         (2019) 9:12524  | https://doi.org/10.1038/s41598-019-48804-y
www.nature.com/scientificreportswww.nature.com/scientificreports/
Southern California, Los Angeles, CA, USA. 68Institute of Environmental Medicine, Karolinska Institutet, Stockholm, 
Sweden. 69Department of Oncology, Södersjukhuset, Stockholm, Sweden. 70Molecular Genetics of Breast Cancer, 
German Cancer Research Center (DKFZ), Heidelberg, Germany. 71Saw Swee Hock School of Public Health, National 
University of Singapore, Singapore, Singapore. 72Department of Surgery, National University Health System, 
Singapore, Singapore. 73Center for Familial Breast and Ovarian Cancer, Faculty of Medicine and University Hospital 
Cologne, University of Cologne, Cologne, Germany. 74Center for Molecular Medicine Cologne (CMMC), Faculty of 
Medicine and University Hospital Cologne, University of Cologne, Cologne, Germany. 75Center for Integrated 
Oncology (CIO), Faculty of Medicine and University Hospital Cologne, University of Cologne, Cologne, Germany. 
76Family Cancer Clinic, The Netherlands Cancer Institute - Antoni van Leeuwenhoek hospital, Amsterdam, The 
Netherlands. 77Department of Medical Oncology, Family Cancer Clinic, Erasmus MC Cancer Institute, Rotterdam, The 
Netherlands. 78Division of Cancer Sciences, University of Manchester, Manchester, UK. 79Center for Clinical Cancer 
Genetics, The University of Chicago, Chicago, IL, USA. 80Division of Cancer Epidemiology and Prevention, Aichi 
Cancer Center Research Institute, Nagoya, Japan. 81Division of Cancer Epidemiology, Nagoya University Graduate 
School of Medicine, Nagoya, Japan. 82Division of Epidemiology, Center for Public Health Sciences, National Cancer 
Center, Tokyo, Japan. 83Department of Genetics and Pathology, Pomeranian Medical University, Szczecin, Poland. 
84Independent Laboratory of Molecular Biology and Genetic Diagnostics, Pomeranian Medical University, Szczecin, 
Poland. 85Department of Gynaecology and Obstetrics, University Hospital Ulm, Ulm, Germany. 86Department of 
Medicine, Division of Oncology, Stanford Cancer Institute, Stanford University School of Medicine, Stanford, CA, 
USA. 87Department of Preventive Medicine, Seoul National University College of Medicine, Seoul, Korea. 88Faculty 
of Medicine, University of Heidelberg, Heidelberg, Germany. 89Department of Genetics and Fundamental Medicine, 
Bashkir State University, Ufa, Russia. 90Department of Surgery, Daerim Saint Mary’s Hospital, Seoul, Korea. 
91Radiation Epidemiology Branch, Division of Cancer Epidemiology and Genetics, National Cancer Institute, 
Bethesda, MD, USA. 92Department of Cancer Genetics, Institute for Cancer Research, Oslo University Hospital-
Radiumhospitalet, Oslo, Norway. 93Institute of Clinical Medicine, Faculty of Medicine, University of Oslo, Oslo, 
Norway. 94Department of Surgery, The University of Hong Kong, Pok Fu Lam, Hong Kong. 95Department of Surgery, 
Hong Kong Sanatorium and Hospital, Happy Valley, Hong Kong. 96VIB Center for Cancer Biology, VIB, Leuven, 
Belgium. 97Laboratory for Translational Genetics, Department of Human Genetics, University of Leuven, Leuven, 
Belgium. 98Epidemiology Program, University of Hawaii Cancer Center, Honolulu, HI, USA. 99Human Genetics 
Division, Genome Institute of Singapore, Singapore, Singapore. 100Department of Epidemiology, University of 
Washington School of Public Health, Seattle, WA, USA. 101Public Health Sciences Division, Fred Hutchinson Cancer 
Research Center, Seattle, WA, USA. 102Division of Health Sciences, Warwick Medical School, University of Warwick, 
Coventry, UK. 103Division of Population Health, Health Services Research and Primary Care, School of Health 
Sciences, Faculty of Biology, Medicine and Health, The University of Manchester, Manchester, UK. 104Unit of Medical 
Genetics, Department of Medical Oncology and Hematology, Fondazione IRCCS Istituto Nazionale dei Tumori di 
Milano, Milan, Italy. 105Department of Clinical Science and Education, Södersjukhuset, Karolinska Institutet, 
Stockholm, Sweden. 106Department of Family Medicine and Public Health, University of California San Diego, La 
Jolla, CA, USA. 107Department of Medical Oncology, University Hospital of Heraklion, Heraklion, Greece. 
108Department of Gynecology and Obstetrics, Ludwig Maximilian University of Munich, Munich, Germany. 109MRC 
Clinical Trials Unit at UCL, Institute of Clinical Trials & Methodology, University College London, London, UK. 
110Precision Medicine, School of Clinical Sciences at Monash Health, Monash University, Clayton, Victoria, Australia. 
111Breast Cancer Research Unit, UM Cancer Research Institute, University of Malaya Medical Centre, Kuala Lumpur, 
Malaysia. 112Department of Laboratory Medicine and Pathobiology, University of Toronto, Toronto, ON, Canada. 
113Laboratory Medicine Program, University Health Network, Toronto, ON, Canada. 114Department of Population 
Sciences, Beckman Research Institute of City of Hope, Duarte, CA, USA. 115Department of Obstetrics and 
Gynecology, Helsinki University Hospital, University of Helsinki, Helsinki, Finland. 116Leuven Multidisciplinary Breast 
Center, Department of Oncology, Leuven Cancer Institute, University Hospitals Leuven, Leuven, Belgium. 117Clinical 
Genetics Research Lab, Department of Cancer Biology and Genetics, Memorial Sloan-Kettering Cancer Center, New 
York, NY, USA. 118Clinical Genetics Service, Department of Medicine, Memorial Sloan-Kettering Cancer Center, New 
York, NY, USA. 119Department of Epidemiology, Gillings School of Global Public Health and UNC Lineberger 
Comprehensive Cancer Center, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA. 120Department of 
Health Sciences Research, Mayo Clinic, Rochester, MN, USA. 121Research Centre for Genetic Engineering and 
Biotechnology ‘Georgi D. Efremov’, Macedonian Academy of Sciences and Arts, Skopje, Republic of Macedonia. 
122Unit of Molecular Bases of Genetic Risk and Genetic Testing, Department of Research, Fondazione IRCCS Istituto 
Nazionale dei Tumori (INT), Milan, Italy. 123Department of Basic Sciences, Shaukat Khanum Memorial Cancer 
Hospital and Research Centre (SKMCH & RC), Lahore, Pakistan. 124Clalit National Cancer Control Center, Carmel 
Medical Center and Technion Faculty of Medicine, Haifa, Israel. 125Medical Oncology Department, Hospital 
Universitario Puerta de Hierro, Madrid, Spain. 126Department of Oncology, University Hospital of Larissa, Larissa, 
Greece. 127Division of Molecular Pathology, The Netherlands Cancer Institute - Antoni van Leeuwenhoek Hospital, 
Amsterdam, The Netherlands. 128Division of Psychosocial Research and Epidemiology, The Netherlands Cancer 
Institute - Antoni van Leeuwenhoek hospital, Amsterdam, The Netherlands. 129Division of Genetics and 
Epidemiology, The Institute of Cancer Research, London, UK. 130Institute of Biomedical Sciences, Academia Sinica, 
Taipei, Taiwan. 131School of Public Health, China Medical University, Taichung, Taiwan. 132Genomics Center, Centre 
Hospitalier Universitaire de Québec – Université Laval Research Center, Québec City, QC, Canada. 133Ss. Cyril and 
Methodius University in Skopje, Medical Faculty, University Clinic of Radiotherapy and Oncology, Skopje, Republic of 
Macedonia. 134Department of Clinical Pathology, The University of Melbourne, Melbourne, Victoria, Australia. 
135Population Oncology, BC Cancer, Vancouver, BC, Canada. 136School of Population and Public Health, University of 
British Columbia, Vancouver, BC, Canada. 137The Curtin UWA Centre for Genetic Origins of Health and Disease, Curtin 
University and University of Western Australia, Perth, Western Australia, Australia. 138Division of Breast Cancer 
Research, The Institute of Cancer Research, London, UK. 139Channing Division of Network Medicine, Department of 
4Scientific RepoRtS |         (2019) 9:12524  | https://doi.org/10.1038/s41598-019-48804-y
www.nature.com/scientificreportswww.nature.com/scientificreports/
Fanconi anemia (FA) is a genetically heterogeneous disorder with 22 disease-causing genes reported 
to date. in some fA genes, monoallelic mutations have been found to be associated with breast cancer 
risk, while the risk associations of others remain unknown. the gene for fA type c, FANCC, has been 
proposed as a breast cancer susceptibility gene based on epidemiological and sequencing studies. 
We used the oncoarray project to genotype two truncating FANCC variants (p.R185X and p.R548X) in 
64,760 breast cancer cases and 49,793 controls of European descent. FANCC mutations were observed 
in 25 cases (14 with p.R185X, 11 with p.R548X) and 26 controls (18 with p.R185X, 8 with p.R548X). 
There was no evidence of an association with the risk of breast cancer, neither overall (odds ratio 0.77, 
95%CI 0.44–1.33, p = 0.4) nor by histology, hormone receptor status, age or family history. We conclude 
that the breast cancer risk association of these two FANCC variants, if any, is much smaller than for 
BRCA1, BRCA2 or PALB2 mutations. if this applies to all truncating variants in FANCC it would suggest 
there are differences between FA genes in their roles on breast cancer risk and demonstrates the merit 
of large consortia for clarifying risk associations of rare variants.
Fanconi Anemia (FA) is a rare recessively inherited disorder characterized by congenital malformations, progres-
sive bone marrow failure and predisposition to cancer. Twenty-two different FA causative genes have now been 
identified whose products act in concert to mediate DNA interstrand crosslink repair1–3. At least seven of them 
(BRCA2/FANCD2, PALB2/FANCN, RAD51C/FANCO, RAD51/FANCR, BRCA1/FANCS, XRCC2/FANCU, and 
RFWD3/FANCW) are involved in different stages of homology-directed recombinational DNA repair (HRR), a 
pathway for error-free maintenance of the genome during replication and after DNA damage. A number of FA 
genes (including BRCA1/FANCS, BRCA2/FANCD1 and PALB2/FANCN) have been shown to be breast cancer 
susceptibility genes3. The products of BRCA1, BRCA2, and PALB2 are central to early stages of HRR. Further 
interactors in this pathway, in particular BRIP1/FANCJ, mainly have been linked to ovarian cancer risk4,5. It is less 
known to what extent other FA gene products may play a role in the inherited component of breast cancer suscep-
tibility. Few of these other FA genes have been tested for mutations in relatively small breast cancer case-control 
studies, thus far6–9.
Early studies suggested that blood relatives of FA patients show an increased risk of breast cancer, although 
these findings have not been corroborated in a replication study and could not assess distinct FA complemen-
tation groups due to lack of genetic information at that time10–13. After FA was stratified into subsets defined by 
complementation assays, an increased risk of breast cancer was attributed to heterozygous carriers of FANCC 
mutations13. Historically, this was the first of the FA genes to be identified and accounts for 8–15% of FA cases14–16. 
More recently, FANCC has been suggested as a candidate breast cancer susceptibility gene in an exome sequencing 
study of 33 familial breast cancer cases and extension to another 438 cases17. However, the evidence for an asso-
ciation between FANCC and breast cancer risk is limited by the low prevalence of mutations17,18, and much larger 
numbers of individuals are needed to provide sufficient power to detect associations of plausible magnitude19.
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In the present study, we genotyped two truncating variants of FANCC (p.R185X and p.R548X) using the 
Oncoarray (see Methods) in 64,760 female breast cancer cases and 49,793 female population controls of European 
descent. Both mutations are disease-causing in European FA patients and are recurrent in the FA mutation 
database20.
Results
We identified the truncating FANCC variants p.R185X (rs121917783) and p.R548X (rs104886457) in 40 of 
153,899 individuals and 20 of 153,904 individuals, respectively. All mutation carriers were heterozygotes. Carrier 
distributions per study and intensity cluster plots for Europeans (which included the majority of mutation car-
riers) are shown in Supplementary Table 1 and Supplementary Fig. 1, respectively. Since the majority of carriers 
were women of European ancestry, we restricted the subsequent case-control association analysis to participants 
from this population. Logistic regression analyses were adjusted for study and 15 principal components21.
In Europeans, the two FANCC variants were observed in 25/64,760 cases (14 with p.R185X, 11 with p.R548X) 
and in 26/49,793 controls (18 with p.R185X, 8 with p.R548X). There was no evidence of association between the 
FANCC variants and breast cancer risk, either for carriers of both variants combined (OR 0.77, 95%CI 0.44–1.33, 
p = 0.35), or for either variant individually (Table 1). Similarly, we found no evidence for an association with 
estrogen receptor (ER)-negative (OR 0.91, 0.35–2.37) or ER-positive (OR 0.67, 0.37–1.28) disease, nor for subsets 
of disease defined by age at diagnosis (<50 years), bilaterality, family history, histological morphology, grade or 
nodal status (Table 2).
For comparison, we also analysed the PALB2/FANCN*p.R414X truncating variant that was genotyped in par-
allel on the same array. This variant was detected in 22/64,780 cases and 3/49,825 controls and was significantly 
associated with risk of breast cancer (OR 5.89, 95%CI 1.76–19.74, p = 0.004). The variant carriers were markedly 
enriched among cases with ER-negative tumours (p = 9.4 × 10−6; pdiff = 0.0006 in a log-likelihood ratio test) and 
specifically triple-negative breast tumours (p = 3.8 × 10−7; pdiff = 0.0001). The p.R414X truncating variant was also 
associated with ductal morphology, a positive first-degree family history of breast cancer, early age at diagnosis 
(<50 years), and low-differentiated tumours (grade 3) (Suppl. Table 1). Hence, by contrast with the two tested 
FANCC variants, p.R185X and p.R548X, the FANCN/PALB2 variant p.R414X was strongly associated with overall 
and with ER-negative disease under the same genotyping and analysis conditions.
Discussion
Functional defects of DNA repair are a hallmark of genomic instability syndromes as well as of carcinogenesis. FA 
is a genome instability and cancer prone disorder that has been investigated for breast cancer predisposition in 
homozygotes and heterozygotes for more than three decades11,12. Monoallelic mutations in five FA genes (BRCA1, 
BRCA2, PALB2, RAD51C, BRIP1) have now been confirmed to predispose to breast or ovarian cancer while bial-
lelic mutations in these genes cause FA3. However, the role of the FA genes most commonly mutated, FANCA and 
FANCC, in the risk of developing breast cancer has remained uncertain. Epidemiological and segregation studies 
have provided some evidence of an increased breast cancer risk for grandmothers of FA patients, particularly 
those who carry the FANCC mutation13.
A previous sequencing study of Australian multiple-case breast cancer families had identified truncating var-
iants in FANCC in 3 of 438 multiple-case breast cancer families but in none of 464 healthy controls, suggestive 
of a predisposing role for FANCC variants in breast cancer17. One of these variants, p.R185X, was also screened 
in our study. p.R185X was first reported shortly after the identification of the FANCC gene, and thus is one of 
the earliest recognized FA-causing mutations. Although representing an apparent nonsense mutation in exon 6, 
it also results in exon 6 being spliced out of a proportion of transcripts, suggesting this variant may alter splice 
site selection, with the aberrant transcript retaining the reading frame22. p.R548X, also an early-detected FANCC 
truncating variant23, is an authentic stop mutation in exon 14, and although in the last exon, it proved to be clearly 
pathogenic for FA24.
The fact that these two disease-causing variants have been frequently observed in European patients with 
FA20 prompted us to investigate their association with breast cancer in a large case-control study. However, we 
did not observe a significant difference between their frequency among breast cancer cases and controls. The 
upper 95% confidence limit was 1.33, thus excluding a two-fold or greater increase in risk found for moderate- or 
high-penetrance alleles in predisposition genes such as CHEK2 and ATM. Moreover, we found no evidence of 
association in subgroups defined by earlier age at onset, a positive family history of breast cancer, bilateral occur-
rence, or defined tumor parameters (histology, grade or hormone receptor status). However, confidence intervals 
for those estimates for subsets were wider as numbers were small – in particular we could not rule out a 2-fold 
increased risk for ER-negative or triple-negative breast cancer.
In contrast, we observed a clear association between the PALB2/FANCN variant p.R414X and breast cancer 
risk. PALB2 is an established breast cancer susceptibility gene, and the investigated mutation p.R414X25 occurred 
Mutation Cases Controls Odds Ratio (95% CI) p
p.R158X 14/64,778 18/49,810 0.64 (0.32; 1.29) 0.215
p.R548X 11/64,788 8/49,816 1.03 (0.41; 2.56) 0.942
All FANCC 25/64,760 26/49,793 0.77 (0.44; 1.33) 0.345
Table 1. Overall analysis of FANCC variants p.R158X and p.R548X. Association analyses of FANCC variants 
p.R158X and p.R548X with overall breast cancer risk. Results are given as odds ratios (OR) with 95% confidence 
interval (CI) and p-value (p).
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at a similar frequency to the tested FANCC mutations. The observed six-fold enrichment of p.R414X in breast 
cancer patients is in line with previous findings for other PALB2 founder mutations26–28 and in the upper range of 
the overall mutational effect size in PALB2 case-control sequencing studies29,30. We confirmed stronger associa-
tions with ER-negative breast cancer, with familial breast cancer and with a high tumor grade31. While genotyping 
arrays such as the Oncoarray are primarily used for evaluating common variants, these data confirm that the 
array provides a robust platform for evaluating even very rare alleles.
Although PALB2 and FANCC are both FA genes, their products exert different roles in the recognition 
and repair of DNA damage. FANCC is a component of the FA core complex which is thought to recognize an 
inter-strand crosslink. FANCL, an E3 ubiquitin ligase in the core complex, ubiquitinates FANCI and FANCD2. 
After many nuclease and translesion polymerase steps, a DNA double stranded intermediate is formed and its 
repair requires proteins from the homology-directed repair pathway, including FANCD1/BRCA2 and FANCN/
PALB2. While truncating variants in BRCA2 and PALB2 confer a substantial risk of breast cancer, our study sug-
gests that truncating FANCC variants do not confer a comparable risk. It is possible that members of the FA core 
complex that act upstream of HRR are less relevant for breast cancer due to their more specialized function in the 
repair of crosslinks while BRCA1, BRCA2, and PALB2 function more globally at DNA double-strand breaks. On 
the other hand, there is some evidence that truncating mutations in another gene involved in the early detection 
of intra-strand crosslinks, FANCM, are associated with both breast and ovarian cancer risk32–34, though FANCM 
is part of an anchor complex rather than the FA core complex and is not considered a classical FA gene35,36. It is 
also possible that the two prototype FANCC truncating variants analysed here, despite being FA-causing, have 
reduced penetrance for breast cancer due to some residual function, and other particular FANCC variants may 
confer a more substantial risk. More work will be required to clarify the role of each FA core complex member for 
breast cancer susceptibility.
In conclusion, our study findings suggest important differences between FA genes, indicating that truncating 
variants in FANCC do not confer a high overall risk of breast cancer unlike PALB2, BRCA1 and BRCA2. Our 
study does not exclude a role of monoallelic FANCC variants as low-penetrance alleles for breast cancer or as a 
genetic risk factor for certain breast cancer subgroups. Very large datasets, such as those generated through the 
BCAC, are critical to evaluate such rare mutations.
Methods
patients. A total of 87 studies from the Breast Cancer Association Consortium (BCAC), of which 78 were 
case-control studies (some nested within prospective cohort studies) and 9 were case-only studies, contributed 
data as summarized in Supplementary Table 1. All studies provided data on disease status and age at diagnosis/
observation, and the majority provided information on clinico-pathological and epidemiological factors, which 
have been curated and incorporated into the BCAC database (version 6). All participating studies were approved 
by their appropriate ethics review boards and all subjects provided informed consent. A list of the ethics review 
boards by study is provided in Supplementary Table 3.
Genotyping. The Illumina OncoArray design and genotyping procedure have been described previously21,37. 
In brief, approximately 72,000 variants were selected, among others, for inclusion on the array specifically for 
their potential relevance to breast cancer, based on prior evidence of association with overall or subtype-specific 
disease, with breast density or with breast tissue specific gene expression. After genotype calling and quality 
control of the cluster file, variants with a call rate <95% in any consortium, not in Hardy-Weinberg equilib-
rium (P < 10−7 in controls or P < 10−12 in cases) or with concordance <98% among 5,280 duplicate pairs were 
excluded. We also excluded samples with extreme heterozygosity (>4.89 standard deviations [SD] from the mean 
for the respective ethnicity). The final dataset, before restriction based on ethnicity, consisted of 153,673 samples 
of which 89,733 were cases and 63,940 were controls.
Stratum Cases Odds Ratio (95% CI) p
ER-negative 5/10,124 0.91 (0.35; 2.37) 0.845
ER-positive 14/40,855 0.67 (0.37; 1.28) 0.223
TNBC 2/4,126 0.89 (0.21; 3.77) 0.877
Ductal 6/36,695 0.33 (0.13; 0.80) 0.014
Lobular 4/6,842 1.27 (0.43; 3.69) 0.665
High grade 3/14,582 0.39 (0.12; 1.31) 0.129
Node-positive 1/15,937 0.14 (0.02; 1.00) 0.050
Familial 7/9,720 1.01 (0.43; 2.35) 0.988
Premenopausal 12/22,232 1.09 (0.55; 2.16) 0.814
Bilateral 0/2,741 — 0.645
Table 2. Analysis of FANCC variants (p.R158X and p.R548X combined) by tumour subtype. Association 
analyses of FANCC variants p.R158X and p.R548X with breast cancer risk for subgroups. Results are given as 
odds ratios (OR) with 95% confidence interval (CI) and p-value (p). Cases in subgroups were compared to the 
frequency 26/ 49,793 for all controls (derived from Table 1). Familial cases were defined as those with a first-
degree family history of breast cancer; premenopausal cases were those with age at diagnosis <50 years. ER, 
estrogen-receptor; TNBC, triple-negative breast cancer.
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Statistical analyses. Per-allele odds ratios and 95% confidence intervals were generated using logis-
tic regression with adjustment for principal components and study. Principal component analysis was per-
formed using data for 33,661 uncorrelated SNPs (which included 2,318 markers of continental ancestry) with a 
MAF ≥ 0.05 and maximum correlation of 0.1, using purpose-written PCcalc software (written by Jonathan Tyrer 
and available at http://ccge.medschl.cam.ac.uk/software/pccalc/).
We also estimated subtype-specific per-allele ORs after restricting the cases by hormone receptor and/or 
HER2/neu status, by tumor grade, by ductal or lobular morphology, by nodal status, by bilateral occurrence of the 
tumor, by early diagnosis (<50 years), and by first-degree family history of breast cancer, using available BCAC 
data for the cases. Since we analysed 3 variants across 10 subgroups, a two-sided p-value ≤ 0.016 for the overall 
analyses and a two-sided p-value ≤ 0.0016 for the subgroup analyses were considered nominally significant.
ethical approval. All experimental protocols were approved by the respective ethical institutions of partic-
ipating BCAC centers. The study was carried out in accordance with the Declaration of Helsinki, and informed 
consent was obtained from all study participants.
Data Availability
The genotyping results from the Oncoarray are available in the dbGAP repository. The FANCC variants analysed 
in the current study are deposited in the NCBI SNP database as rs121917783 and rs104886457. The datasets an-
alysed during the current study are available from the corresponding author upon reasonable request and with 
permission of the Data Access Committee of the Breast Cancer Association Consortium.
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